Amid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data
Fuente:
FierceBiotech
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of Merck & Co.